Akso Health Group closed its fiscal 2026 year on March 31 with its core marketing-promotion revenue down again, its medical-device sales finally at nil, and - far more consequentially - its once-substantial cash balance reduced to nearly nothing. The reported numbers tell a stark story: net revenue of $13.8 million, a negative gross profit, a $18.7 million net loss, and cash on hand of just $170,572 at year-end against $176.2 million a year earlier. What makes the period unusual is not the shrinking top line, which fell 6.4%, but what happened to the money. Over the course of fiscal 2026 the company paid out roughly $175.7 million to five vendors as advances for developing software modules for a planned internet-hospital business, then - after the fiscal year closed, in June 2026 - terminated those agreements and collected the full amount back. Management and the auditor both anchor the company's ability to continue as a going concern on that single June refund, not on the underlying business, which operated at a gross loss and consumed $12.8 million of operating cash during the year.
The share structure complicates every valuation read. The company ended the year with roughly 2.57 billion ordinary shares outstanding, up from about 1.65 billion a year earlier, after cashless warrant exercises and prior private placements. At a reference price of $1.39, that implies a market capitalization in the low-to-mid $3 billion range using the company's own reported share count - several times larger than a $13.8 million revenue base and far above the $180.9 million of reported equity - while quoted market caps on retail data portals, at around $1.2 billion on a materially smaller share count, point to the extreme instability of any single market-cap figure for a name this heavily diluted. Quoted per-share earnings are meaningless: the company lost $0.01 per share on a weighted roughly 2.2 billion shares. This is a balance-sheet story, not an earnings story, and the balance sheet's headline asset is a refund the company already received after year-end.